Journal article

Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine

Catrin E Moore, Branwen J Hennig, Kirsten P Perrett, J Claire Hoe, Sue J Lee, Helen Fletcher, Denise Brocklebank, Daniel O'Connor, Matthew D Snape, Andrew J Hall, Shelley Segal, Adrian VS Hill, Andrew J Pollard

Clinical and Vaccine Immunology | AMER SOC MICROBIOLOGY | Published : 2012


Awarded by Medical Research Council

Funding Acknowledgements

This work was supported by Novartis Vaccines and Diagnostics (NVD), who funded the initial clinical study and genotyping. NVD also provided funding and sponsorship for the infant study, allowing DNA collection by the investigators. GlaxoSmithKline Biologicals and the Oxford Partnership Comprehensive Biomedical Research Centre provided funding for the clinical study of 6- to 12-year-old children, which was sponsored by Oxford University, facilitating DNA collection. M.D.S. was funded by the Oxford Partnership Comprehensive Biomedical Research Centre, with funding from the NIHR Biomedical Research Centre Programme, which, with the NIHR Thames Valley Comprehensive Local Research Network, also provides support to the Oxford Vaccine Group.M.D.S. has received financial assistance from Novartis Vaccines and GlaxoSmithKline to attend conferences and has had travel and accommodation expenses paid by Novartis Vaccines while working in collaboration with Novartis Vaccines in Siena, Italy. A.J.P. acts as chief and principal investigator for clinical trials conducted on behalf of Oxford University, sponsored by vaccine manufacturers, including Novartis Vaccines and GlaxoSmithKline, but does not receive any personal payment from them. Industry-sourced honoraria for lecturing or writing and travel expenses and grants for educational activities are paid directly to an independent charity or an educational/administrative fund held by the Department of Paediatrics, University of Oxford.